HG146
Phase 2Small molecule
HG146 is one of 15 small molecule programs targeting Adenoid Cystic Carcinoma. It is currently in Phase 2.
1
Indications
3
Total Trials
1
Active Trials
14
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
15 competitors in Adenoid Cystic Carcinoma
#DrugCompanyPhaseTrials
1Adriamycin
PfizerApproved
Afinitor
NovartisApproved
Lenvima
EisaiPhase 2
Keytruda
Merck & Co.Phase 2
Rybrevant
Johnson & JohnsonPhase 2
Ellence
PfizerPhase 2
Padcev
PfizerPhase 2
Zanzalintinib
Merck & Co.Phase 2
Becotatug Vedotin
FFudan University
Phase 2
Verzenio
Eli LillyPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Multiple Myeloma1 trial
Lymphoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HG146. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- HHitGen Inc.